Vivani Medical Statistics
Total Valuation
Vivani Medical has a market cap or net worth of $103.48 million. The enterprise value is $96.83 million.
| Market Cap | 103.48M |
| Enterprise Value | 96.83M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivani Medical has 86.24 million shares outstanding. The number of shares has increased by 19.67% in one year.
| Current Share Class | 86.24M |
| Shares Outstanding | 86.24M |
| Shares Change (YoY) | +19.67% |
| Shares Change (QoQ) | +13.89% |
| Owned by Insiders (%) | 51.36% |
| Owned by Institutions (%) | 7.71% |
| Float | 35.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.06 |
| P/TBV Ratio | 5.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.96.
| Current Ratio | 3.18 |
| Quick Ratio | 3.02 |
| Debt / Equity | 0.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -176.41% and return on invested capital (ROIC) is -51.12%.
| Return on Equity (ROE) | -176.41% |
| Return on Assets (ROA) | -44.69% |
| Return on Invested Capital (ROIC) | -51.12% |
| Return on Capital Employed (ROCE) | -78.18% |
| Weighted Average Cost of Capital (WACC) | 18.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$644,929 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.00% in the last 52 weeks. The beta is 3.29, so Vivani Medical's price volatility has been higher than the market average.
| Beta (5Y) | 3.29 |
| 52-Week Price Change | -10.00% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 48.28 |
| Average Volume (20 Days) | 168,968 |
Short Selling Information
The latest short interest is 335,967, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 335,967 |
| Short Previous Month | 392,626 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 1.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.82M |
| Pretax Income | -27.09M |
| Net Income | -27.09M |
| EBITDA | -27.36M |
| EBIT | -27.82M |
| Earnings Per Share (EPS) | -$0.40 |
Balance Sheet
The company has $19.75 million in cash and $18.28 million in debt, with a net cash position of $1.47 million or $0.02 per share.
| Cash & Cash Equivalents | 19.75M |
| Total Debt | 18.28M |
| Net Cash | 1.47M |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | 19.09M |
| Book Value Per Share | 0.23 |
| Working Capital | 14.77M |
Cash Flow
In the last 12 months, operating cash flow was -$25.35 million and capital expenditures -$1.17 million, giving a free cash flow of -$26.52 million.
| Operating Cash Flow | -25.35M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 452,000 |
| Net Borrowing | 46,000 |
| Free Cash Flow | -26.52M |
| FCF Per Share | -$0.31 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vivani Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.67% |
| Shareholder Yield | -19.67% |
| Earnings Yield | -27.55% |
| FCF Yield | -26.98% |
Analyst Forecast
The average price target for Vivani Medical is $3.75, which is 212.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.75 |
| Price Target Difference | 212.50% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |